

## DESCRIPTION


<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human PSGL-1/CD162 in direct ELISAs.
<b>Source</b>	Monoclonal Mouse IgG <sub>2A</sub> Clone # 688101
<b>Purification</b>	Protein A or G purified from hybridoma culture supernatant
<b>Immunogen</b>	Chinese hamster ovary cell line CHO-derived recombinant human PSGL-1/CD162 Gln42-Gly295 Accession # NP_002997
<b>Conjugate</b>	Allophycocyanin Excitation Wavelength: 620-650 nm Emission Wavelength: 660-670 nm
<b>Formulation</b>	Supplied in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details.  *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
<b>Flow Cytometry</b>	10 $\mu$ L/10 <sup>6</sup> cells	See Below

## DATA



## PREPARATION AND STORAGE

<b>Shipping</b>	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
<b>Stability &amp; Storage</b>	<b>Protect from light. Do not freeze.</b> <ul style="list-style-type: none"> <li>12 months from date of receipt, 2 to 8 °C as supplied.</li> </ul>

**BACKGROUND**

Human PSGL-1 (P-Selectin Glycoprotein Ligand-1; also CD162), is a 120 kDa mucin-type glycoprotein that plays a key role in leukocyte adhesion (1-3). It is synthesized as a 412 amino acid (aa) preproprecursor that contains a 17 aa signal sequence, a 24 aa propeptide, a 279 aa extracellular domain (ECD), a 21 aa transmembrane segment and a 71 aa cytoplasmic region (4, 5). Following cleavage of the pre- and prosegments, it is expressed as a 240 kDa disulfide-linked homodimer. The extreme N-terminus (aa 1-16 of the mature molecule) contains one threonine (aa 16) and three tyrosines (aa 5, 7, and 10) that are involved in ligand binding. The Thr residue allows for O-linked glycosylation in the form of a core-2 structure (GalNAc-Gal) linked in a  $\beta$ 1,6 bond to a sialylated Lewis X motif (GlcNAc linked to both Fuc and Gal with a terminal sialic acid residue) (1, 2, 5, 6, 7). The three tyrosine residues allow for sulfation (8, 9). When binding to P-selectin, Tyr sulfation and glycosylation are essential. Tyr7 provides the most efficient sulfate moiety, while Fuc and sialic acid are essentially mandatory (7). When binding to E-selectin, only carbohydrate is needed, while both carbohydrate and Tyr10 are used for L-selectin binding (6, 8). There are 16 decameric aa repeats in the ECD of the longform of PSGL-1. This form is referred to as the A allele, and represents 65 - 80% of the population. Alleles B and C show deletions of decameric repeats #2 (aa 132-141) plus #9 and 10 (aa 222-241), respectively. Shorter forms may show weaker binding to P-selectin (9, 10). Soluble forms of PSGL-1 are also known. Neutrophil elastase will cleave somewhere within repeats #5-9, while cathepsin G cleaves after Tyr7 (11). The loss of Tyr5 and 7 should impact binding affinity. PSGL-1 is found on virtually all leukocytes and macrophages/DC's (1). Although there is similarity in the organization of the ECD between species, there is little aa identity. Human PSGL-1 ECD shares 51%, 52% and 43% aa sequence identity with equine, canine and mouse ECD, respectively.

**References:**

1. Yang, J. *et al.* (1999) *Thromb. Haemost.* **81**:1.
2. Cummings, R.D. (1999) *Braz. J. Med. Biol. Res.* **32**:519.
3. McEver, R.P. and R.D. Cummings (1997) *J. Clin. Invest.* **100**:485.
4. Sako, D. *et al.* (1993) *Cell* **75**:1179.
5. Veldman, G.M. *et al.* (1995) *J. Biol. Chem.* **270**:16470.
6. Bernimoulin, M.P. *et al.* (2003) *J. Biol. Chem.* **278**:37.
7. Leppanen, A. *et al.* (2000) *J. Biol. Chem.* **275**:39569.
8. Sako, D. *et al.* (1995) *Cell* **83**:323.
9. Afshar-Kharghan, V. *et al.* (2001) *Blood* **97**:3306.
10. Lozano, M.L. *et al.* (2001) *Br. J. Haematol.* **115**:969.
11. Gardiner, E.E. *et al.* (2001) *Blood* **98**:1440.